TetraLogic Ends Birinapant MDS Trial After No Clinical Benefit Seen Over Placebo

TetraLogic Pharmaceuticals Corp has ended a placebo controlled Phase II study of birinapant co-administered with azacitidine in first line patients suffering from the blood disorder myelodysplastic syndromes (MDS) after the SMAC-mimetic failed to show any clinical benefit over placebo.